Amphastar Pharmaceuticals, Inc 8-K, filed Jun 8, 2021
Amphastar Pharmaceuticals, Inc. (AMPH)
About this 8-K
Amphastar Pharmaceuticals, Inc filed this 8-K on June 8, 2021, reporting on events of June 7, 2021.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of Registrant as specified in its charter)
| | | | |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
| ||
| ||
(Address of principal executive offices) | (zip code) |
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.07. Submission of Matters to a Vote of Security Holders.
On June 7, 2021, the Company held its Annual Meeting virtually via a live webcast. The stockholders of the Company voted on the following items at the Annual Meeting:
| 1. | To elect four Class II directors to serve until the 2024 annual meeting of stockholders or until their respective successors are duly elected and qualified; |
| 2. | To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2021; and |
| 3. | To approve, on an advisory basis, the compensation of our named executive officers. |
The voting results for the proposals are detailed below.
1. Election of Directors
Nominee | For | Against | Abstained | Broker Non-votes |
Mary Ziping Luo | 29,158,736 | 6,352,716 | 34,540 | 5,412,880 |
Howard Lee | 18,829,594 | 16,677,548 | 38,850 | 5,412,880 |
Michael A. Zasloff | 29,474,826 | 5,701,209 | 369,957 | 5,412,880 |
Gayle Deflin | 35,328,641 | 178,661 | 38,690 | 5,412,880 |
Each director nominee was duly elected to serve until the 2024 annual meeting of stockholders and until his or her successor is duly elected and qualified.
2. Ratification of Appointment of Independent Registered Public Accounting Firm
For | Against | Abstained | Broker Non-votes |
40,435,839 | 472,037 | 50,996 | N/A |
The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
3. The Compensation of our Named Executive Officers
For | Against | Abstained | Broker Non-votes |
34,818,379 | 666,412 | 61,201 | 5,412,880 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMPHASTAR PHARMACEUTICALS, INC. | |
Date: June 8, 2021 |
| |
| By: /s/ William J. Peters |
|
| William J. Peters | |
| Chief Financial Officer and Executive Vice President | |
| | |